Brazil has suspended the contract for 20 million doses of Bharat Biotech International’s Covaxin worth about $320 million following a controversy over alleged irregularities in procurement and pricing. The contract between Bharat Biotech and Brazil’s Precisa Medicamentos has been at the centre of a political storm following a report by the parliamentary commission of inquiry on the Bolsonaro administration’s handling …
